Tech Transfer Deals, July 2016: Kite Moves Toward Off-The-Shelf T-Cell Therapy
Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.
You may also be interested in...
Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.